Cancer name Skin Cutaneous Melanoma
Cancer Type SKCM
Immunotherapy type Immunostimulant OR Targeting Therapy
Treatment cGAMP
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Gene
Signature Ifn-β1
Official Symbol IFNB1
Mode of action TRAN_D_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental mouse model
Description mRNA expression analysis 4 h after injection revealed expression of Ifn-β1 but not of Ifn-α genes such as Ifn-α2,Ifn-α5,andIfn-α6, indicating that intratumoral STING activation triggers an early type I IFN activity via the induction of Ifn-β1 expression.
PMID 26607445
Title STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity.